Lessons from Theranos: Private Unicorn Scrutiny and Technical Debt in High-Risk Industries

Jason Lemkin discusses key lessons from Theranos's problems, emphasizing that private unicorns face greater scrutiny than expected, technical debt eventually catches up with companies, and hard science innovation requires more experience than typical software startups. He argues that the biotech/medical device industry may not be suitable for the dorm-room startup narrative that works in software.